Navigation Links
Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
Date:12/12/2012

CLEVELAND, Dec. 12, 2012 /PRNewswire/ -- Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA's Office of Orphan Products Development for treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength.

The program is currently in a Phase I/II trial at Nationwide Children's Hospital in adult patients with Becker muscular dystrophy and inclusion body myositis, a trial funded by the foundation Parent Project Muscular Dystrophy. "The Orphan Drug designation will provide incentives for Milo Biotechnology's continued development of the therapy in rare muscular dystrophies with the greatest medical need," said CEO Al Hawkins. "We hope that our potent muscle strengthening approach will someday augment emerging genetic strategies to transform care for these intractable diseases."

Duchenne muscular dystrophy is the most common inherited myopathy, caused by the absence of dystrophin protein. Becker muscular dystrophy, a less severe form of Duchenne muscular dystrophy, is caused by reduced levels of dystrophin protein. With both types, patients experience progressive muscle weakness, and cardiac and respiratory complications.

The Orphan Drug Act (ODA) grants special status for products to treat rare diseases. Orphan designation qualifies the sponsor of the product for a tax credit and seven years of marketing exclusivity via the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee. The disease or condition for which the drug is intended must affect fewer than 200,000 people in the United States.   

About Milo Biotechnology Milo Biotechnology is an early clinical stage startup company developing therapies to strengthen muscle and improve the lives of patients with neuromuscular diseases.
'/>"/>

SOURCE Milo Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Puma Biotechnology Announces Completion of Private Placement
2. Animal Biotechnology - Technologies, Markets and Companies
3. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
4. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
5. JumpStart Invests $250,000 in Milo Biotechnology
6. Global Biotechnology Industry
7. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
8. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Global Biotechnology Instrumentation Industry
11. Choose New Jersey, Inc. to Tout New Jerseys Life Sciences Hub At Worlds Largest Biotechnology Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, announced today its ... held in San Francisco, CA. ... Chief Executive Officer, will present on Monday, January 12, ... presentation will be webcast live and may be accessed ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... the fiscal 2009 third quarter and nine-month period ended ... for its fiscal year 2009 now ending on February, ... period ended February 28, 2009 in the range of ...
... regular improvements in information technology, says Slava Rotkin, but ... Take the laptop, for example. Its components, especially its ... while the instrument,s power and capacity increase. But heat ... melt and the laptop hardware to fail. , Indeed, ...
... Approval for SIMPONI , ... Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: ... granted approval of SIMPONI (TM) (golimumab),as a once-monthly, ... active rheumatoid arthritis (RA), active psoriatic arthritis (PsA),and ...
Cached Biology Technology:Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5New 'near-field' radiation therapy promises relief for overheating laptops 2New 'near-field' radiation therapy promises relief for overheating laptops 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... have an enormous carbon footprint, but often energy is ... comfortable temperature. Research to be published in the ... shows how the ubiquity of smart phones connected to ... and reduce heating or air conditioning for unused spaces. ...
... "robust" jaw and skull bones was a muscular creature with ... than previously thought, scientists have discovered., Researchers found a partial ... dated to 1.34 million years old and belonging to ... site in Tanzania. The find, published in the latest edition ...
... widespread fascination with sharks, the world,s oldest ocean predators have ... a great white shark,s genetic code has fished up big ... since before dinosaurs roamed. Cornell researchers have discovered that ... an array of different functions including metabolism match ...
Cached Biology News:The heat is on...or off 2Discovery of partial skeleton suggests ruggedly built, tree-climbing human ancestor 2New genetic research finds shark, human proteins stunningly similar 2
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
Request Info...
Request Info...
Biology Products: